Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired MET amplification in non-small cell lung cancer is highly associated with the exposure of EGFR inhibitors and may not affect patients' outcome.

Experimental and molecular pathology - 1 Feb 2021

Yin Wei, Liu Wei, Guo Ming, Tang Zhenya, Toruner Gokce, Robinson Melissa, Cheng Joanne, Hu Shimin, Medeiros L Jeffrey, Tang Guilin

Abstract excerpt

MET amplification has been associated with shorter survival in cancer patients and thought to represent one of two major mechanisms for developing resistance to therapy with EGFR inhibitors. We retrospectively studied 99 patients who had non-small cell lung cancer (NSCLC) and had at least two FISH analyses for MET/CEP7 at different time points during the course of disease. Four (4%) patients showed MET...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gene Amplification

Share to Gene Expression Regulation, Neoplastic

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Share to Survival Rate

Source

Identifiers

PMID: 33189723
DOI: 10.1016/j.yexmp.2020.104572

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired MET amplification in non-small cell lung cancer is highly associated with the exposure of EGFR inhibitors and may not affect patients' outcome.PMID 33189723Read ↗

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitorsSemantic proximity Read ↗

Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition.Semantic proximity Read ↗

Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosisSemantic proximity Read ↗

Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.Semantic proximity Read ↗

MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations.Semantic proximity Read ↗

MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Crizotinib in Patients With MET-Amplified NSCLC.Semantic proximity Read ↗

Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogiesSemantic proximity Read ↗

MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)Semantic proximity Read ↗

Copy number gain of MET gene with low level in a metastatic lung adenocarcinoma patient represents response to salvage treatment with savolitinib and osimertinib: a case reportSemantic proximity Read ↗

Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification.Semantic proximity Read ↗

<i>MET</i> Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the LungSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.